Pharming Group N.V.
PHGUF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $97 | $93 | $79 | $93 |
| % Growth | 4.4% | 17.9% | -14.7% | – |
| Cost of Goods Sold | $7 | $9 | $8 | $12 |
| Gross Profit | $90 | $84 | $71 | $80 |
| % Margin | 92.7% | 90.4% | 89.5% | 86.8% |
| R&D Expenses | $23 | $24 | $21 | $22 |
| G&A Expenses | $17 | $21 | $22 | $46 |
| SG&A Expenses | $51 | $52 | $57 | -$39 |
| Sales & Mktg Exp. | $34 | $31 | $35 | -$85 |
| Other Operating Expenses | -$0 | -$2 | -$0 | $91 |
| Operating Expenses | $74 | $73 | $78 | $74 |
| Operating Income | $16 | $11 | -$7 | $7 |
| % Margin | 16.3% | 11.6% | -8.9% | 7.2% |
| Other Income/Exp. Net | -$3 | -$4 | -$5 | -$0 |
| Pre-Tax Income | $13 | $7 | -$12 | $7 |
| Tax Expense | $5 | $3 | $3 | $4 |
| Net Income | $8 | $5 | -$15 | $4 |
| % Margin | 7.8% | 5% | -18.6% | 3.9% |
| EPS | 0.011 | 0.007 | -0.022 | 0.005 |
| % Growth | 61.4% | 131.8% | -540% | – |
| EPS Diluted | 0.011 | 0.007 | -0.022 | 0.005 |
| Weighted Avg Shares Out | 669 | 685 | 669 | 680 |
| Weighted Avg Shares Out Dil | 669 | 685 | 669 | 680 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $1 |
| Interest Expense | $8 | $0 | $5 | $2 |
| Depreciation & Amortization | $3 | $3 | $3 | $8 |
| EBITDA | $23 | $10 | -$4 | $16 |
| % Margin | 24.1% | 10.5% | -5.2% | 16.9% |